Zobrazeno 1 - 10
of 758
pro vyhledávání: '"Thomas Sj"'
Autor:
Christopher Kaczor, Thomas, SJ Sherman
Thomas Aquinas on the Cardinal Virtues provides essential passages from Thomas's treatment of the cardinal virtues in the Summa theologiae, edited and explained for classroom use or the independent reader. Arranged for beginners, this book contains p
Publikováno v:
In Obstetrics, Gynaecology & Reproductive Medicine April 2020 30(4):126-129
Dendritic action potentials exhibit long plateaus of many tens of milliseconds, outliving axonal spikes by an order of magnitude. The computational role of these slow events seems at odds with any need to rapidly integrate and relay information throu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57b527c3d8a485d63d6806b84fd33c66
https://doi.org/10.1101/2023.03.22.533815
https://doi.org/10.1101/2023.03.22.533815
Autor:
Schmid, Benedikt1 (AUTHOR), Smith, Thomas SJ2 (AUTHOR) smith@fss.muni.cz
Publikováno v:
Progress in Human Geography. Apr2021, Vol. 45 Issue 2, p253-275. 23p.
Autor:
Smith, Thomas SJ1 (AUTHOR) thomas.smith@geographie.uni-muenchen.de
Publikováno v:
Local Economy. May2023, Vol. 38 Issue 3, p242-263. 22p.
Autor:
Dennis Barnes, Anurita Rohilla, Alex Bickerton, Robert Ej Ryder, Rajeev Raghavan, Abcd Empagliflozin Audit Contributors, Suzanne Phillips, Devesh Sennik, Ian W. Gallen, Alison Evans, Siva Sivappriyan, Jackie Elliott, Thomas Sj Crabtree
Publikováno v:
British Journal of Diabetes. 21:62-66
Introduction: Evidence from phase III and the EMPA-REG OUTCOME trials have demonstrated improvements in renal endpoints with empagliflozin use. The EMPA-KIDNEY trial is currently underway and is assessing whether there are benefits of empagliflozin i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f8032bf1aab37d075dc2d017d9a6b27
https://doi.org/10.15277/bjd.2021.288
https://doi.org/10.15277/bjd.2021.288
Autor:
Ken Darzy, Thomas Sj Crabtree, Anurita Rohilla, Iskandar Idris, Abcd Canagliflozin Audit Contributors, Rajeev Raghavan, Alex Bickerton, Alison Evans, Peter H. Winocour, Robert E.J. Ryder, Mahender Yadagiri, Suzanne Phillips, Devesh K. Sennik
Publikováno v:
British Journal of Diabetes. 20:113-116
Introduction: Canagliflozin was initially approved for use in the UK in March 2013. Randomised control trial evidence has demonstrated multiple beneficial effects. Many of these are present at initial follow-up and within 26 weeks of randomised contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8d8ea9105274ba697d46acfaba5417c
https://doi.org/10.15277/bjd.2020.258
https://doi.org/10.15277/bjd.2020.258
Autor:
Anurita Rohilla, Suzanne Phillips, Thomas Sj Crabtree, Alison Evans, Susannah Rowles, Ian W. Gallen, Robert E.J. Ryder, Mahender Yadagiri, Iskandar Idris, Devesh K. Sennik, Alex Bickerton
Publikováno v:
British Journal of Diabetes. 20:19-24
Introduction: People with type 2 diabetes are known to be at increased risk of non-alcoholic fatty liver disease (NAFLD). There is increasing evidence of diabetes treatments with benefits of also improving NAFLD. Although mostly focused on glucagon-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c7e91d464a608155604aac80dd5f3a4
https://doi.org/10.15277/bjd.2020.239
https://doi.org/10.15277/bjd.2020.239
Publikováno v:
British Journal of Diabetes. 20:28-31
Imeglimin is a novel, first in-class, blood glucose-lowering agent which acts via a mitochondrial mechanism to enhance glucose-induced insulin secretion, decrease hepatic glucose output and increase glucose uptake by skeletal muscle. A systematic rev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9a71dbe1f6a38993478b9e19d122796
https://doi.org/10.15277/bjd.2020.247
https://doi.org/10.15277/bjd.2020.247
Autor:
Anastasios Gazis, Thomas Sj Crabtree
Publikováno v:
Obstetrics, Gynaecology & Reproductive Medicine. 30:126-129
The use of technologies to support self-management of type 1 diabetes is growing, including in women pursuing pregnancy. Women with type 1 diabetes might use a variety of technologies to manage their diabetes before, during and after pregnancy. Innov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbf211605138255ef71b97aa60be148f
https://doi.org/10.1016/j.ogrm.2020.02.002
https://doi.org/10.1016/j.ogrm.2020.02.002